切除不能肝細胞癌およびチャイルドピューB7およびB8肝硬変患者を対象に、ベバシズマブの有無にかかわらずアテゾリズマブを評価する研究 (Kirros)
切除不能な肝細胞癌およびチャイルド・ピューB7およびB8肝硬変患者を対象とした第II相、非盲検、多コホート、多施設共同研究
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85724
- University of Arizona Cancer Center
-
-
California
-
La Jolla、California、アメリカ、92093
- UC San Diego Moores Cancer Center
-
Los Angeles、California、アメリカ、90089-5601
- University of Southern California-Keck School of Medicine -1975 Zonal Ave
-
Newport Beach、California、アメリカ、92663
- University of Southern California
-
Orange、California、アメリカ、92868
- University of California Irvine Medical Center
-
Pasadena、California、アメリカ、91105-2561
- California Liver Research Institute
-
Sacramento、California、アメリカ、95817
- University of California Davis Medical Center
-
Stanford、California、アメリカ、94305
- Stanford Health Care
-
Torrance、California、アメリカ、90502-2006
- Harbor UCLA Medical Center
-
West Hollywood、California、アメリカ、90048-2422
- Cedars Sinai Comprehensive Transplant Center
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- Hartford Healthcare Cancer Institute at Hartford Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20037
- George Washington University- Medical Faculty Associates
-
Washington D.C.、District of Columbia、アメリカ、20422-0001
- Washington DC VA Medical Center
-
-
Florida
-
Orlando、Florida、アメリカ、32806
- Orlando Health Inc.
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611-2908
- Northwestern University
-
Chicago、Illinois、アメリカ、60612-4795
- University of Illinois Health Outpatient Care Center
-
Chicago、Illinois、アメリカ、60637-1426
- The Duchossois Center for Advanced Medicine
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536-7001
- University of Kentucky - Markey Cancer Center
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70805
- LSU Health Baton Rouge
-
Baton Rouge、Louisiana、アメリカ、70808-4300
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Health System
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke?s Hospital of Kansas City
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08901
- Rutgers Cancer Institute of New Jersey
-
Newark、New Jersey、アメリカ、07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
New York
-
Mineola、New York、アメリカ、11501-4064
- NYU Langone Hospital - Long Island
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center
-
The Bronx、New York、アメリカ、10468-3904
- James J Peters Veterans Administration Medical Center - NAVREF
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Levine Cancer Institute
-
-
Ohio
-
Dayton、Ohio、アメリカ、45428-9000
- Dayton VA Medical Center - NAVREF - PPDS
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104-5020
- The University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hillsboro、Oregon、アメリカ、97124-5806
- Kaiser Permanente Westside Medical Center
-
Portland、Oregon、アメリカ、97239-3011
- OHSU Knight Cancer Institute Hematology Oncology
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- Jefferson Health Honickman Center
-
Pittsburgh、Pennsylvania、アメリカ、15240
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
-
-
Tennessee
-
Germantown、Tennessee、アメリカ、38138-1762
- The West Clinic (East Campus)
-
Nashville、Tennessee、アメリカ、37208-2918
- Nashville General Hospital at Meharry
-
-
Texas
-
Dallas、Texas、アメリカ、75390-0001
- University of Texas Southwestern Medical Center
-
Dallas、Texas、アメリカ、75246-2008
- Texas Oncology (Worth) - USOR
-
Dallas、Texas、アメリカ、75203-1260
- Liver Institute at Methodist Dallas
-
Dallas、Texas、アメリカ、75235
- Moody Outpatient Center ? Parkland Health
-
Denison、Texas、アメリカ、75020-0084
- Texas Oncology - Denison Cancer Center
-
Houston、Texas、アメリカ、77025-1669
- Kelsey Research Foundation
-
Houston、Texas、アメリカ、77030-4211
- Michael E Debakey VA Medical Center - NAVREF - PPDS
-
-
Utah
-
Murray、Utah、アメリカ、84107-5741
- Intermountain Healthcare
-
St. George、Utah、アメリカ、84790
- Intermountain Cancer Center
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042
- Inova Schar Cancer Institute
-
Richmond、Virginia、アメリカ、23226-1925
- Bon Secours St. Mary's Hospital
-
Richmond、Virginia、アメリカ、23298-5028
- VCU Medical Center North Hospital
-
-
Washington
-
Seattle、Washington、アメリカ、98101
- Virginia Mason Medical Center
-
-
-
-
-
Rio Piedras、プエルトリコ、00935
- Pan American Center for Oncology Trials, LLC
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
General Inclusion Criteria:
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
- Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
- Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
- Adequate hematologic and end-organ function
- Life expectancy of at least 12 weeks
- Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
- Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
- Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
- Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
- Serum bilirubin ≤ 3 × ULN
- Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
- Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
- International normalized ratio (INR) ≤2.3
General Exclusion Criteria:
- Pregnancy or breastfeeding
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medication
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
- Inadequately controlled hypertension
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
- Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Prior allogeneic stem cell or solid organ transplantation
- Actively listed for liver transplantation
- Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
- Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
- History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
- Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
- Participants with ascites controlled on diuretics are allowed
- History of spontaneous bacterial peritonitis within last 12 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Cohort A: Atezolizumab+Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
他の名前:
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.
他の名前:
|
|
実験的:Cohort B: Atezolizumab
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs)
時間枠:Baseline through the end of the study (up to approximately 36 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B. |
Baseline through the end of the study (up to approximately 36 months)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- ML44719
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。